Nusinersen

(Spinraza)

Nusinersen

Drug updated on 11/13/2023

Dosage FormInjection (intrathecal; 12 mg/5 mL)
Drug ClassSurvival motor neuron-2 (SMN2)-directed antisense oligonucleotides
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Product Monograph / Prescribing Information

Document TitleYearSource
Spinraza (nusinersen) Prescribing Information.2023Biogen, Cambridge, MA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2023Brain Sciences
Evaluation of the therapeutic efficacy and tolerability of current drug treatments on the clinical outcomes of paediatric spinal muscular atrophy type 1: A systematic review.2023Paediatric Respiratory Reviews
Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: A systematic review and meta-analysis.2023Frontiers in Paediatrics
Clinical, pharmacoeconomic, and stakeholder input combined report.2022CADTH
Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: A systematic review and meta-analysis.2022Frontiers in Pediatrics
Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.2022Medicina
Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.2022Neurotherapeutics
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis.2021Orphanet Journal of Rare Diseases
Nusinersen treatment of spinal muscular atrophy – a systematic review.2020Danish Medical Journal
Drug treatment for spinal muscular atrophy types II and III.2020Cochrane Database of Systematic Reviews
Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.2019Acta Neurologica Belgica
Clinical review report (resubmission): nusinersen (Spinraza).2019CADTH
Drug treatment for spinal muscular atrophy type I.2019Cochrane Database of Systematic Reviews
Spinraza® and Zolgensma® for spinal muscular atrophy: effectiveness and value.2019ICER
Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.2018Neurology

Clinical Practice Guidelines